Donor and recipient characteristics
| . | BMHSCT group (N = 28) . | PBHSCT group (N = 21) . | P . |
|---|---|---|---|
| Age, y, median (range) | |||
| Recipients | 33 (16-50) | 35 (21-49) | .50 |
| Donors | 37 (20-63) | 33 (21-50) | .38 |
| Sex mismatch (donor/recipient) | |||
| Female/female (parous donor) | 3 (11%) [2] | 3 (14%) [1] | |
| Female/male (parous donor) | 6 (21%) [2] | 6 (29%) [6] | |
| Male/female | 11 (39%) | 4 (19%) | |
| Male/male | 8 (29%) | 8 (38%) | .50 |
| Donor pregnancies | |||
| Nulliparous female | 5 (18%) | 2 (10%) | |
| Parous female | 4 (14%) | 7 (33%) | |
| Male | 19 (68%) | 12 (57%) | .34 |
| ABO group mismatch | |||
| Identical | 15 (54%) | 10 (48%) | |
| Minor | 8 (29%) | 7 (33%) | |
| Major | 4 (14%) | 3 (14%) | |
| Minor + major | 1 (3%) | 1 (5%) | .96 |
| Diagnosis | |||
| ALL | 7 (25%) | 2 (9%) | |
| AML | 10 (36%) | 10 (48%) | |
| CML | 11 (39%) | 9 (43%) | .48 |
| Conditioning regimen | |||
| TBI-EDX | 17 (61%) | 13 (62%) | |
| BUS-EDX | 6 (21%) | 5 (24%) | |
| VP16-EDX-TBI or TAME | 5 (18%) | 3 (14%) | 1 |
| . | BMHSCT group (N = 28) . | PBHSCT group (N = 21) . | P . |
|---|---|---|---|
| Age, y, median (range) | |||
| Recipients | 33 (16-50) | 35 (21-49) | .50 |
| Donors | 37 (20-63) | 33 (21-50) | .38 |
| Sex mismatch (donor/recipient) | |||
| Female/female (parous donor) | 3 (11%) [2] | 3 (14%) [1] | |
| Female/male (parous donor) | 6 (21%) [2] | 6 (29%) [6] | |
| Male/female | 11 (39%) | 4 (19%) | |
| Male/male | 8 (29%) | 8 (38%) | .50 |
| Donor pregnancies | |||
| Nulliparous female | 5 (18%) | 2 (10%) | |
| Parous female | 4 (14%) | 7 (33%) | |
| Male | 19 (68%) | 12 (57%) | .34 |
| ABO group mismatch | |||
| Identical | 15 (54%) | 10 (48%) | |
| Minor | 8 (29%) | 7 (33%) | |
| Major | 4 (14%) | 3 (14%) | |
| Minor + major | 1 (3%) | 1 (5%) | .96 |
| Diagnosis | |||
| ALL | 7 (25%) | 2 (9%) | |
| AML | 10 (36%) | 10 (48%) | |
| CML | 11 (39%) | 9 (43%) | .48 |
| Conditioning regimen | |||
| TBI-EDX | 17 (61%) | 13 (62%) | |
| BUS-EDX | 6 (21%) | 5 (24%) | |
| VP16-EDX-TBI or TAME | 5 (18%) | 3 (14%) | 1 |
BMHSCT indicates bone marrow hematopoietic stem cell transplantation; PBHSCT, peripheral blood hematopoietic stem cell transplantation; ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; TBI, total body irradiation (median, 12 Gy [range, 11-13.5]); EDX, cyclophosphamide (120 mg/kg); BUS, busulfan (16 mg/kg per os); VP16, vepeside (20 mg/kg); TAME, TBI + aracytine (12 g/m2) + melphalan (140 mg/m2) + etoposide (60 mg/kg).